Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?

Ann Oncol. 2023 Jul;34(7):567-568. doi: 10.1016/j.annonc.2023.05.011.

Authors

F Mosele¹, M Di Maio²

Affiliations

¹ INSERM U981, Gustave Roussy, Villejuif, France; Breast Cancer Unit, Department of Medical Oncology, Gustave Roussy, Villejuif, France. Electronic address: mariafernanda.mosele@gustaveroussy.fr.
² Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy.

PMID: 37349024
DOI: 10.1016/j.annonc.2023.05.011

No abstract available

Publication types

Editorial

MeSH terms

Breast Neoplasms* / drug therapy
Camptothecin
Female
Humans
Immunoconjugates*
Receptor, ErbB-2
Trastuzumab / therapeutic use

Substances

trastuzumab deruxtecan
Trastuzumab
Camptothecin
Immunoconjugates
Receptor, ErbB-2